The Effect of Pancreatoduodenectomy Plus Intraperitoneal Hyperthermic Perfusion on Resectable Pancreatic Head Cancer: Cohort Study

Feng, Feng; Cao, Xuehui; Liu, Xueqing; Qin, Jianzhang; Zhang, Shubin; Li, Qiusheng; Liu, Jianhua

doi:10.1245/s10434-020-09095-0

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, HIPEC was administered using chemotherapy drugs, with additional intraperitoneal hyperthermic perfusion using only normal saline. Intraperitoneal hyperthermic perfusion with normal saline has been proven to improve survival outcomes in pancreatic cancer without increasing the risk of complications ( 30 , 31 ). Thus, the combination of HIPEC with chemotherapy drugs and normal saline was thought to strengthen the antitumor effect of HIPEC.…”

Section: Discussionmentioning

confidence: 99%

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study

et al. 2022

View full text Add to dashboard Cite

ObjectiveTo study the efficacy of interval debulking surgery (IDS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) compared to IDS alone for the treatment of ovarian cancer after neoadjuvant chemotherapy (NACT).MethodsWe conducted a retrospective study of patients with stage IIIC/IV high-grade serous ovarian carcinoma who underwent surgery at our center from January 2018 to December 2019. Patients who underwent IDS after NACT with (N = 20) or without (N = 42) HIPEC were included. HIPEC was administered after surgery and was combined with 1–2 courses of intraperitoneal hyperthermic perfusion with normal saline only. We analyzed clinical information and outcomes for the two groups.ResultsThe median progression-free survival (PFS) was 14.05 months in the IDS plus HIPEC group and 12.97 months in the IDS group (P = 0.597). The median overall survival (OS) was not reached. After adjustment for age between the two groups, the differences in PFS and OS remained nonsignificant. The change ratio of postoperative CA-125 to preoperative CA-125 was 0.66 in the IDS plus HIPEC group and 0.53 in the IDS group (P = 0.341). The difference in human epididymis protein 4 (HE-4) change ratio between the two groups was nonsignificant (P = 0.225). No significant difference was observed in the occurrence of grade 3 and 4 adverse events between the two groups (P = 0.201).ConclusionAfter NACT, IDS plus HIPEC did not show significant PFS and tumor index change ratio benefits over IDS alone in patients with primary ovarian cancer. Further investigations are needed to assess the role of HIPEC in the treatment of ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The photothermal therapy (PTT) uses the nano-particles loading with a photothermal transducer (PTA) and the laser to form a laser absorption peak thus better confining the thermal energy in the target [ 27 , 28 , 29 , 30 , 31 ]. Hyperthermic-isolated limb perfusion (HILP) [ 32 ], intraperitoneal hyperthermic perfusion (IPHP) [ 33 ], and intrapleural hyperthermic perfusion (IHP) [ 34 ] are also available hyperthermia modalities. The heating power of the above thermal ablation technologies can all be controlled to the hyperthermia range.…”

Section: Current Thermal Therapy Technique For Cancermentioning

confidence: 99%

Synergetic Thermal Therapy for Cancer: State-of-the-Art and the Future

et al. 2022

View full text Add to dashboard Cite

As a safe and minimal-invasive modality, thermal therapy has become an effective treatment in cancer treatment. Other than killing the tumor cells or destroying the tumor entirely, the thermal modality results in profound molecular, cellular and biological effects on both the targeted tissue, surrounding environments, and even the whole body, which has triggered the combination of the thermal therapy with other traditional therapies as chemotherapy and radiation therapy or new therapies like immunotherapy, gene therapy, etc. The combined treatments have shown encouraging therapeutic effects both in research and clinic. In this review, we have summarized the outcomes of the existing synergistic therapies, the underlying mechanisms that lead to these improvements, and the latest research in the past five years. Limitations and future directions of synergistic thermal therapy are also discussed.

show abstract

“…First, hyperthermia could damage tumour cells directly by inducing the denaturation of membrane proteins and DNA synthetase. For patients with pancreatic cancer, pancreaticoduodenectomy combined with intraperitoneal hyperthermic perfusion was demonstrated to be superior to pancreaticoduodenectomy alone in overall survival and 2-year survival rates [ 8 ]. A phse III clinical trial verified that the median overall survival time of patients with ovarian cancer receiving postoperative hyperthermic intraperitoneal chemotherapy was 69.5 months which was longer than that in patients receiving normothermic intraperitoneal chemotherapy (61.3 months, p < 0.05) [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Hyperthermia inhibits cellular function and induces immunogenic cell death in renal cell carcinoma

Huaqi,

Bingqi,

Yanhui

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background In recent years, hyperthermia has been widely applied as a novel strategy for cancer treatment due to its multiple antitumour effects. In particular, the potential influences of hyperthermia on the tumour immune microenvironment may improve the efficacy of immunotherapies. However, the effect of hyperthermia on renal cell carcinoma (RCC) has not been well characterized until now. Methods In the present study, we primarily evaluated the effects of hyperthermia on cellular function via cellular proliferation, migration, invasion and apoptosis assays. In addition, the influence of hyperthermia on the immunogenicity of RCC cells was analysed using flow cytometry analysis, enzyme-linked immunosorbent assays, and immunofluorescent (IF) staining. Results Our results demonstrate that hyperthermia significantly inhibits RCC cell proliferation, migration, and invasion and promotes cell apoptosis. In addition, we verified that hyperthermia improves the immunogenicity of RCC cells by inducing immunogenic cell death. Conclusion Our findings suggest that hyperthermia is a promising therapeutic strategy for RCC.

show abstract

The Effect of Pancreatoduodenectomy Plus Intraperitoneal Hyperthermic Perfusion on Resectable Pancreatic Head Cancer: Cohort Study

Cited by 4 publications

References 22 publications

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study

Synergetic Thermal Therapy for Cancer: State-of-the-Art and the Future

Hyperthermia inhibits cellular function and induces immunogenic cell death in renal cell carcinoma

Contact Info

Product

Resources

About